India Insulin Market
Review to 2018 - Intensifying Strategic Alliances Between Companies presents a comprehensive analysis of market size by value of major types of
insulin consumed in India. The report entails the segment wise market share
analysis and company profiles of major players in the insulin market in India.
The future analysis of the market has also been discussed in the report.
 |
| India Insulin Market |
The economic advancement of any country is paradoxical in
nature. While on one hand it increases the affluence of the masses, the other
side is characterized by diseases that are accompanied by passive lifestyles.
From the several diseases caused by a sedentary form of life such as
cardiovascular ailments, hypertension and high blood pressure, diabetes is also
increasing at an alarming rate, especially in the developing countries. India
was resident to nearly 61.5 million people suffering from diabetes in 2013,
which is the second largest in the world after China. The prevalence of
diabetes has made it the fifth largest disease in India.
Diabetes in India is reaching
epidemic proportions. Rapid cultural changes such as increasing urbanization,
modified diet patterns and sedentary lifestyles among the young generation,
have heightened the prevalence of diabetes in India. In 2013, while 61.5
million people suffered from diabetes in the country, another 30 million were
in the pre-diabetes group. Medication for the diabetic population is the need
of the hour since the disease is adding significantly to the mortality rate of
India.
In FY’2008, the revenue
generated by the sales of insulin in India was estimated to be USD ~ million
and reached USD ~ million in FY’2013, following at a CAGR of 13.9% during the
period. The Indian insulin market is witnessing development and has yet to
mature. With a huge base of diabetic patients, it is anticipated that only 25%
of this population is receiving treatment. Unawareness backed by low affordability
has left the major proportion of the diabetic populace to remain untreated.
However, since higher disposable income is increasing the accessibility to
healthcare services, enhanced diagnostics will further broaden the patient
base, creating opportunities for insulin companies operating in India.
The diabetic population in India is largely treated with
human insulin solely due to the fact that it is cheaper as compared to analog
insulin. In FY’2013, human insulin held ~% of the total insulin market in India,
generating revenue of USD ~ million. The revenue from human insulin registered
a CAGR of 10.5% during FY’2008-FY’2013. Although the share of human insulin has
been more since FY’2008, the market captured by analog insulin has been growing
rapidly with a CAGR of 20.4% during FY’2008-FY’2013, increasing its share from
~% in FY’2008 to ~% in FY’2013.
India has become a very lucrative market for insulin
multinationals. Companies including Novo Nordisk, Eli Lilly and Sanofi dominate
the landscape and had a share of more than ~% in the Indian insulin market in
FY’2013. With superior product portfolios and marketing strategies, the 3
companies have gained a monopoly over the market. Domestic enterprises
including Biocon and Wockhardt therefore face stiff competition from the
foreign counterparts.
Key Topics Covered in
the Report
·
The market size of India insulin market in terms
of revenue
·
Market segmentation by insulin replacement
therapy and types of insulin
·
Government regulation and support schemes for
the Indian insulin market
·
Pricing scenario of different insulin brands in
India
·
Trends and developments in India insulin market
·
Growth drivers and challenges in India insulin
market
·
Market share of major players in the insulin
market in India
·
Market share of major players by types of
insulin
·
Company profiles of major players in the Indian
insulin market
·
Future outlook and projections of the insulin
market in India
·
Macroeconomic factors affecting the insulin
market in India
Table of Contents:
1. Asia Pacific Insulin Market Introduction
1.1. Asia Pacific Insulin Market Value Chain
1.2. Asia Pacific Insulin Market Size by Value, 2008-2013
1.3. Asia Pacific Insulin Market Segmentation, 2008-2013
1.3.1. By Geography, 2008-2013
1.3.2. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), 2013
1.3.3. By Types of Insulin (Premix, Rapid Acting, Long Acting), 2013
1.4. New Product Development By Major Insulin Companies
1.5. Trends and Developments in Asia Pacific Insulin Market
Monopoly of Foreign Brands
Phasing Out of Human Insulin
1.6. Growth Drivers and Challenges in Asia Pacific Insulin Market
Shift from Human Insulin to Analog Insulin
Rising Prevalence of Diabetes
Increasing Diabetes Care Expenditure
Low Affordability
Lack of Awareness
1.7. SWOT Analysis of Asia Insulin Market
1.8. Asia Pacific Insulin Market Future Outlook and Projections, 2014-2018
1.8.1. By Geography, 2014-2018
2. India Insulin Market Introduction
3. India Insulin Market Size, FY’2008-FY’2013
4. India Insulin Market Segmentation, FY’2008-FY’2013
4.1. By Insulin Replacement Therapy (Human Insulin and Analog Insulin), FY’2008-FY’2013
4.2. By Types of Insulin (Premix, Rapid Acting, long Acting), FY’2008-FY’2013
4.3. Usage by Type of Diabetes, FY’2008-FY’2013
5. Government Regulations and Support Schemes in India Insulin Market
5.1. National Pharmaceutical Pricing Authority (NPPA)
Implications of Pricing Limits by NPPA
5.2. National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS)
6. Pricing Scenario in India Insulin Market
7. Trends and Developments in India Insulin Market
Price Gap Between Foreign and Domestic Insulin Brands
Shift of Diabetes to Young Age Group
Strategic Alliances in India Insulin Market
8. Growth Drivers and Challenges in India Insulin Market
Increasing Diabetic Population
Increasing Expenditure on Diabetes Care
Exchange Rate Fluctuation
9. Market Share of Major Companies in India Insulin Market, FY’2013
9.1. By Type of Insulin, FY’2013
9.1.1. By Premix Insulin, FY’2013
9.1.2. By Long Acting Insulin, FY’2013
9.1.3. By Rapid Acting Insulin, FY’2013
10. Company Profiles of Major Players in India Insulin Market
10.1. Novo Nordisk India Pvt. Ltd
10.1.1. Company Overview
10.1.2. Business Strategies
Market Expansion Through Spreading Awareness
Strengthening Research and Development (R&D) Activities
10.1.3. Competitive Standing
10.2. Eli Lilly and Company India Pvt. Ltd.
10.2.1. Company Overview
10.2.2. Business Strategies
Focus on Increasing R&D Investment in India
Concentration Towards the Diabetes Care Segment
10.2.3. Competitive Standing
10.3. Sanofi India Ltd.
10.3.1. Company Overview
10.3.2. Business Strategies
Commence Insulin Production in India
Product Innovation
Patient Awareness Programs
10.3.3. Competitive Standing
10.4. Biocon Ltd.
10.4.1. Company Overview
10.4.2. Competitive Standing
10.5. Wockhardt Ltd.
10.5.1. Company Overview
10.5.2. Competitive Standing
11. India Insulin Market Future Outlook and Projections, 2014-2018
11.1. By Insulin Replacement Therapy (Human Insulin and Analog Insulin, FY’2014-FY’2018
11.2. Cause and Effect Relationship Between Dependable and Independent Variable Factors prevailing in India Insulin Market
12. Macroeconomic Factors in India Insulin Market, 2008-2018
12.1. Diabetic Population in India, 2008-2018
12.2. India Government Spending on Healthcare, FY’2008-FY’2018
12.3. India Consumer Spending on Healthcare, FY’2008-FY’2018
12.4. India Personal Disposable Income, FY’2008-FY’2018
13. Appendix
13.1. Market Definitions
13.2. Abbreviations
13.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Final Conclusion
13.4. Disclaimer
Browse and Download Report Here - http://www.kenresearch.com/healthcare/pharmaceutical-industry/india-insulin-market-research-report/573-91.html
No comments:
Post a Comment